Novo Nordisk A/S (NVO) Q2 FY2026 6-K Filings and Company Events
More for Novo Nordisk A/S: Company index · Financial statements · 20-F and 6-K summary
PeriodQ2 FY2026
Published
This page digests the material Form 6-K filings Novo Nordisk A/S (NVO) has made over roughly the trailing five quarters: earnings releases, management and board changes, capital returns, financing, and governance actions. Each item cites the SEC accession number of the filing it came from. It is current through Q2 FY2026, the period ended 2026-06-30, as reported in the 6-K filed with the SEC.
Novo Nordisk is a foreign private issuer and reports current events on Form 6-K. Amounts are converted from Danish kroner (DKK) to US dollars at Federal Reserve H.10 rates for the relevant period (average for flows, closing rate for the per-ADR dividend); percentage changes are as stated by the company, in its own currency or at constant exchange rates (CER). One ADR represents one B share.
Filings that contain financial statements
- Form 6-K, filed 4 August 2026, accession 0000353278-26-000023 (Company Announcement No 48/2026): unaudited interim financial report for the period 1 January to 30 June 2026 (Q2 and H1 2026), prepared under IAS 34. It contains the condensed income statement (Appendix 1), condensed cash flow statement (Appendix 2), condensed balance sheet (Appendix 3), condensed statement of changes in equity (Appendix 4), adjusted sales split and sales reconciliations (Appendices 5-6) and non-IFRS measures (Appendix 7). This is the source for the current interim numbers.
- Form 6-K, 4 August 2026, accession 0001171843-26-005184: pre-announcement of Q2 2026 adjusted sales and adjusted operating profit with a headline results table only; not a set of financial statements.
- No other 6-K in this period carries financial statements. The annual statements for 2025 are in the Form 20-F filed 4 February 2026 (accession 0000353278-26-000012).
Earnings and guidance
- 4 August 2026 - raised 2026 outlook (accessions 0001171843-26-005184 and 0000353278-26-000023). Adjusted sales growth is now expected at 0% to -6% at CER and adjusted operating profit growth at 0% to -6% at CER, up from -4% to -12% for both on 6 May 2026. Novo attributed the raise to higher expectations for GLP-1 product sales. On a non-adjusted basis the mid-point of 2026 sales and operating profit growth would be 5% and 12%.
- Q2 2026 results (0000353278-26-000023). Reported net sales were DKK 78,488 million ($12.22 billion), up 2% in DKK and 3% at CER. Adjusted sales rose 7% at CER. Reported operating profit was DKK 27,061 million ($4.21 billion), down 16% at CER, hurt by a DKK 2,649 million ($402.53 million) 340B rebate provision reversal in Q2 2025 and by non-cash impairment charges of DKK 6,328 million ($984.86 million) on intangible pipeline assets, including DKK 4.0 billion ($622.54 million) for monlunabant. Adjusted operating profit was DKK 33,389 million ($5.20 billion), up 11% at CER. Reported H1 2026 sales were up 18% at CER, helped by a DKK 26.8 billion ($4.20 billion) non-cash reversal of US 340B Drug Pricing Program rebate provisions in Q1 2026; adjusted H1 sales were up 2% at CER. Adjusted Obesity care sales grew 16% at CER in Q2.
- Commercial. Wegovy pill (US launch 5 January 2026) exceeded 265,000 weekly prescriptions for the week ending 17 July 2026 and more than 5 million prescriptions since launch; Wegovy HD (7.2 mg) launched in the US on 7 April. Wegovy pill and Wegovy 7.2 mg single-dose pen received EU approval in July 2026. The Medicare Part D "Bridge" pilot for obesity medicines began 1 July 2026.
Pipeline and regulatory
- 31 July 2026 - ZEUS phase 3 trial of ziltivekimab did not reduce major adverse cardiovascular events (MACE) versus placebo in people with ASCVD, chronic kidney disease and inflammation (hazard ratio 0.99; 95% CI 0.88-1.11). Novo said the outcome "will result in a non-cash impairment charge in Q3 2026" and "will not impact" the previously communicated 2026 adjusted operating profit outlook; the HERMES and ARTEMIS outcomes trials continue, with readouts expected in H1 2027 (6-K 0001171843-26-005109). The 4 August report (0000353278-26-000023) later says it "may result" in the impairment.
- 17 September 2026 - CHMP positive opinion for FREHEMGO (denecimig) in haemophilia A, with or without inhibitors, in adults and children. Novo expects first European launches in Q4 2026 and a broad EU rollout from early 2027 (0001171843-26-006088).
- 2 October 2026 - FDA review of denecimig BLA extended. The FDA told Novo the review (submitted September 2025, decision originally anticipated in Q3 2026) is still ongoing with no new action date, citing ongoing manufacturing facility remediation; it did not identify deficiencies in clinical efficacy or safety data. Novo says there is no impact on its 2026 outlook and aims for a US launch in the first half of 2027, pending a decision (0001171843-26-006374).
Capital allocation
- Share repurchases. Novo is executing a programme of up to DKK 15 billion ($2.33 billion) over the 12 months from 4 February 2026, including a tranche of up to DKK 11.2 billion ($1.74 billion) running from 6 May 2026 to 1 February 2027. Weekly 6-K reports through 5 October 2026 (accession 0001171843-26-006440) show 36,604,179 B shares repurchased since 4 February 2026 for DKK 10.25 billion ($1.59 billion) as of 2 October 2026, and 50,644,876 treasury shares (1.1% of share capital). In H1 2026 Novo returned DKK 41.2 billion ($6.43 billion) to shareholders: DKK 35.3 billion ($5.51 billion) in dividends and DKK 5.9 billion ($921.08 million) in buybacks (0000353278-26-000023).
- Interim dividend of DKK 3.75 per share (about $0.58 per ADR): ex-date 14 August 2026 (17 August for ADRs), record date 17 August, paid 18 August for shares and 25 August for ADRs (0000353278-26-000023).
- Debt. On 21 May 2026 Novo repaid its maturing EUR 1.30 billion bond and on 11 June 2026 issued CHF 1.09 billion of bonds in four tranches under its EMTN programme; ratings are Aa3 (Moody's) and AA (S&P) (0000353278-26-000023).
- Free cash flow for H1 2026 was DKK 55.3 billion ($8.63 billion), under a free cash flow definition revised from Q1 2026 (0000353278-26-000023).
Legal and regulatory
Per the legal matters section of the 4 August 2026 report (0000353278-26-000023):
- 18 May 2026: the US Supreme Court denied Novo's certiorari petition in its challenge to the Inflation Reduction Act pricing provisions; the matter is closed.
- Cipla has filed an ANDA for generic Ozempic with a Paragraph IV certification; Novo has sued for patent infringement in New Jersey.
- Novo is a defendant in putative US class actions over an IT security incident announced on 11 June 2026.
- 30 June 2026: Sandoz filed a Unified Patent Court action in Milan seeking revocation of Novo's unitary patent covering the 1 mg semaglutide dose for diabetes in 18 EU countries.
- 21 July 2026: Novo sued Eli Lilly in federal court in New Jersey alleging false advertising over comparative GLP-1 efficacy claims.
Management
No change to the executive team or board was reported in the period. On 6 August 2026 (accession 0001171843-26-005375) Novo reported vesting of 74 shares each (about $3,364 per person) under the 100th Anniversary restricted share programme to board members and executives including the CEO and CFO; this is routine.
Not in SEC filings to date
No merger or acquisition, signed or closed, appears in the 6-Ks in this period.
FAQ · Novo Nordisk A/S 6-K filings and events
What has Novo Nordisk A/S (NVO) reported in its recent 6-K filings?
Novo Nordisk A/S (NVO): Form 6-K, filed 4 August 2026, accession 0000353278-26-000023 (Company Announcement No 48/2026): unaudited interim financial report for the period 1 January to 30 June 2026 (Q2 and H1 2026), prepared under IAS 34. It contains the condensed income statement (Appendix 1), condensed cash flow statement (Appendix 2), condensed balance sheet (Appendix 3), condensed statement of changes in equity (Appendix 4), adjusted sales split and sales reconciliations (Appendices 5-6) and non-IFRS measures (Appendix 7). This is the source for the current interim numbers.
When does Novo Nordisk A/S (NVO) next file with the SEC?
Novo Nordisk A/S (NVO) is expected to file its next Form 6-K with the SEC on or around November 4, 2026. That date is a projection rather than a company-announced date: it is derived from Novo Nordisk A/S's own filing history with the SEC, by taking the date the company filed the same fiscal period a year earlier and adding 52 weeks. The most recent periodic report on file is the 6-K for Q2 FY2026, the period ended 2026-06-30, SEC accession 0000353278-26-000023.
Related companies
How this page was built
This page was built from eight of Novo Nordisk A/S's own filings with the SEC, read one at a time. Nothing on it is taken from news coverage, analyst commentary or another website. Their accession numbers are cited inline, so any statement here can be traced to the filing it came from and checked against sec.gov.
A single company files thousands of pages with the SEC in a year, and no two companies file them the same way, so the reading and the assembly here are done by AI rather than by rules that break on the differences. Every pass is then audited back against the filings it came from before the page is published, and anything the filings do not support is left out and named rather than filled in. AI can still make mistakes. That is why the accession numbers are printed: the filing is the authority, and this page is a route to it.
Published by Ticker Scout, an independent publisher of company filings data. About Ticker Scout · Disclaimer
Built from Novo Nordisk A/S's SEC filings by Ticker Scout; accession numbers are cited throughout so every figure can be checked against sec.gov. Free to cite with attribution: Ticker Scout (tickerscout.ai). Not investment advice, see the Disclaimer.